Predictors and impacts of second-line chemotherapy on survival after progression in patients with advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Teramukai, S.
Nishimura, T.
Nakagawa, M.
Kawahara, M.
Kubota, K.
Furuse, K.
Fukushima, M.
机构：
[1] Kyoto Univ Hosp, Kyoto, Japan
[2] Natl Kinki Chuo Chest Med Ctr, Osaka, Japan
[3] Natl Canc Ctr Hosp East, Chiba, Japan
[4] Japan Multinatl Trial Org, Kyoto, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7675
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Combination of anlotinib and second-line chemotherapy as surrogate to reduce immunosuppression in patients with advanced non-small cell lung cancer
    Lou, Zhi
    Wang, Xin
    Hu, Chenxi
    Liu, Weixuan
    Ji, Yajun
    [J]. PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2024, 40 (07) : 1509 - 1515
  • [32] Histologic review of second-line permetrexed treatment in patients with non-small cell lung cancer (NSCLC)
    Virani, S.
    Almubarak, M.
    Rogers, J. S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [33] Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC)
    Ondhia, Umang
    Conter, H. J.
    Owen, Scott
    Zhou, Anna
    Nam, Julian
    Singh, Sumeet
    Abdulla, Ahmed
    Chu, Paula
    Felizzi, Federico
    Paracha, Noman
    Sanghag, Randeep
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (07) : 625 - 637
  • [34] Efficacy and safety of second-line immunotherapy in patients with advanced non-small cell lung cancer
    Sanchez Escudero, Laura
    Cobelas Cartagena, Stephanie S.
    Sanchez Esperilla, Maria
    Bayo, Juan L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [35] Pemetrexed as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): Efficacy and correlation with molecular markers
    Blasco, A.
    Sirera, R.
    Terrasa, J.
    Provencio, M.
    Guillen, C.
    Maestu, I.
    de las Penas, R.
    Bover, I.
    Berdiel, M.
    de Aguirre, I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] Chemotherapy for advanced non-small cell lung cancer (NSCLC)
    Manegold, C
    [J]. LUNG CANCER, 2002, 38 : S47 - S50
  • [37] Response to chemotherapy as a predictor of survival in advanced non-small cell lung cancer (NSCLC)
    Soussi, Ghassen
    Racil, Hajer
    Bacha, Saoussen
    Rouhou, Sana Cheikh
    Zidi, Asma
    Ayadi, Aida
    Chaouch, Nawel
    Chabbou, Abdellatif
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [38] Efficacy of First-line Chemotherapy Affects the Second-Line Setting Response in Patients with Advanced Non-Small Cell Lung Cancer
    Cao, Wa
    Li, Ai-Wu
    Ren, Sheng-Xiang
    Chen, Xiao-Xia
    Li, Wei
    Gao, Guang-Hui
    He, Ya-Yi
    Zhou, Cai-Cun
    [J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (16) : 6799 - 6804
  • [39] Quality of life and survival in patients receiving chemotherapy for advanced non-small cell lung cancer (NSCLC)
    St-Pierre, D. M.
    Kreisman, H.
    Kasymjanova, G.
    Agulnik, J. S.
    Swanson, T.
    Pepe, C.
    Lajeunesse, L.
    Gagne, S.
    Dajczman, E.
    Pereira, L.
    Small, D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [40] Docetaxel and carboplatin as second-line chemotherapy for metastatic non-small cell lung cancer
    Laack, E
    Dierlamm, T
    Knuffmann, C
    Popp, J
    Schmied, B
    Dürk, H
    Wacker-Backerhaus, G
    Zeller, W
    Verpoort, K
    Fiedler, W
    Hossfeld, DK
    [J]. LUNG CANCER, 2002, 36 (03) : 303 - 307
12345